Eli Lilly to sell low blood sugar drug to Amphastar
April 24 (Reuters) - Eli Lilly and Co LLY.N will sell
its low blood sugar drug Baqsimi to Amphastar Pharmaceuticals
AMPH.O for over $500 million in cash, the two companies said
on Monday.
Amphastar will pay $500 million at closing and another $125
million in cash after one year under the deal.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj
Kalluvila)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Amphastar Pharmaceuticals,
See all newsU.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Amphastar Q1 revenue and adjusted EPS miss estimates
Brief: Amphastar Pharmaceuticals Q1 EPS USD 0.14
Brief: Amphastar Pharmaceuticals Inc - Authorizes $50 Million Increase To Share Buyback Program On March 12, 2026 - SEC Filing
Brief: Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing